Impact of Basiliximab on regulatory T-cells early after kidney transplantation: Down-regulation of CD25 by receptor modulation

Transplant International

Volumn 23, Issue 5, 2010, Pages 514-523

  Vondran, Florian Wolfgang Rudolf ^a   Timrott, Kai ^a   Tross, Janice ^a   Kollrich, Sonja ^a   Schwarz, Anke ^a   Lehner, Frank ^a   Klempnauer, Juergen ^a   Becker, Thomas ^a   Schwinzer, Reinhard ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Anti IL 2R; Basiliximab; Down regulation; Modulation; Regulatory T cells; Transplantation

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL LOSS; CLINICAL ARTICLE; DOWN REGULATION; DRUG EFFECT; DRUG RESEARCH; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE FUNCTION; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; BIOPSY; BIOSYNTHESIS; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOLOGY; IMMUNOLOGY; KIDNEY; METABOLISM; MIDDLE AGED; PROCEDURES;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BIOPSY; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, REGULATORY;

EID: 77950638599     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2009.01013.x     Document Type: Article

References (36)

1. Nashan B, Schwinzer R, Schlitt HJ, Wonigeit K, Pichlmayr R. Immunological effects of the anti-IL-2 receptor monoclonal antibody BT 563 in liver allografted patients. Transpl Immunol 1995 3 : 203.
2. Nashan B, Schlitt HJ, Schwinzer R, et al. Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients. Transplantation 1996 61 : 546. (Pubitemid 26073597)
3. Soulillou JP. Immunosuppression through inhibition of interleukin-2/interleukin-2 receptor interaction. Transplant Proc 1999 31 : 49S.
4. Koch M, Niemeyer G, Patel I, Light S, Nashan B. Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation. Transplantation 2002 73 : 1640. (Pubitemid 34568679)
5. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001 167 : 1245.
6. Jiang S, Lechler RI, He XS, Huang JF. Regulatory T cells and transplantation tolerance. Hum Immunol 2006 67 : 765. (Pubitemid 44572599)
7. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005 6 : 345. (Pubitemid 41716771)
8. Kang SM, Tang Q, Bluestone JA. CD4+CD25+ regulatory T cells in transplantation: progress, challenges and prospects. Am J Transplant 2007 7 : 1457.
9. Joffre O, Santolaria T, Calise D, et al. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med 2008 14 : 88.
10. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003 4 : 330.
11. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006 203 : 1701. (Pubitemid 44036276)
12. Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006 203 : 1693. (Pubitemid 44036275)
13. Lohr J., Knoechel B, Abbas AK. Regulatory T cells in the periphery. Immunol Rev 2006 212 : 149. (Pubitemid 44116706)
14. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997 350 : 1193. (Pubitemid 127445091)
15. Vincenti F, de Andres A, Becker T, et al. Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients. Transpl Int 2006 19 : 446. (Pubitemid 43736340)
16. Bluestone JA, Liu W, Yabu JM, et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008 8 : 2086.
17. Bloom DD, Chang Z, Fechner JH, et al. CD4+CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant 2008 8 : 793.
18. Amlot PL, Rawlings E, Fernando ON, et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995 60 : 748.
19. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008 8 : 753. (Pubitemid 351347767)
20. Demirkiran A, Hendrikx TK, Baan CC, van der Laan LJ. Impact of immunosuppressive drugs on CD4+CD25+FOXP3 + regulatory T cells: does in vitro evidence translate to the clinical setting? Transplantation 2008 85 : 783. (Pubitemid 351440740)
21. Couper KN, Blount DG, de Souza JB, Suffia I, Belkaid Y, Riley EM. Incomplete depletion and rapid regeneration of Foxp3 + regulatory T cells following anti-CD25 treatment in malaria-infected mice. J Immunol 2007 178 : 4136. (Pubitemid 46492363)
22. Kohm AP, McMahon JS, Podojil JR, et al. Cutting Edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells. J Immunol 2006 176 : 3301.
23. Kreijveld E, Koenen HJ, Klasen IS, Hilbrands LB, Joosten I. Following anti-CD25 treatment, a functional CD4+CD25+ regulatory T-cell pool is present in renal transplant recipients. Am J Transplant 2007 7 : 249. (Pubitemid 44952880)
24. Baan CC, van der Mast BJ, Klepper M, et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 2005 80 : 110. (Pubitemid 40980903)
25. Wang Z, Shi BY, Qian YY, Cai M, Wang Q. Short-term anti-CD25 monoclonal antibody administration down-regulated CD25 expression without eliminating the neogenetic functional regulatory T cells in kidney transplantation. Clin Exp Immunol 2009 155 : 496.
26. Onrust SV, Wiseman LR. Basiliximab. Drugs 1999 57 : 207 discussion 214.
27. Kovarik JM, Pescovitz MD, Sollinger HW, et al. Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. Clin Transplant 2001 15 : 123.
28. Bram RJ, Hung DT, Martin PK, Schreiber SL, Crabtree GR. Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. Mol Cell Biol 1993 13 : 4760.
29. Hocker B, Kovarik JM, Daniel V, et al. Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedication. Transplantation 2008 86 : 1234.
30. Game DS, Hernandez-Fuentes MP, Lechler RI. Everolimus and basiliximab permit suppression by human CD4+CD25+ cells in vitro. Am J Transplant 2005 5 : 454.
31. Warle MC, Kwekkeboom J, Tilanus HW, Metselaar HJ. Basiliximab interferes with the detection of soluble IL-2 receptor by the Immulite Immunoassay system. J Immunol Methods 2003 275 : 133. (Pubitemid 36351548)
32. Mullberg J, Rauch CT, Wolfson MF, et al. Further evidence for a common mechanism for shedding of cell surface proteins. FEBS Lett 1997 401 : 235. (Pubitemid 27056123)
33. Yates J, Rovis F, Mitchell P, et al. The maintenance of human CD4+ CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro. Int Immunol 2007 19 : 785. (Pubitemid 47073268)
34. Vang KB, Yang J, Mahmud SA, Burchill MA, Vegoe AL, Farrar MA. IL-2, -7, and -15, but not thymic stromal lymphopoeitin, redundantly govern CD4+Foxp3+ regulatory T cell development. J Immunol 2008 181 : 3285.
35. Mitchell P, Afzali B, Lombardi G, Lechler RI. The T helper 17-regulatory T cell axis in transplant rejection and tolerance. Curr Opin Organ Transplant 2009 14 : 326.
36. Hendrikx TK, Klepper M, Ijzermans J, Weimar W, Baan CC. Clinical rejection and persistent immune regulation in kidney transplant patients. Transpl Immunol 2009 21 : 129.